1. Uncategorized

Hub Transitions Need Proven Plans, Smart Scale-Up

Written by Posted on Less than 0 min read

Today’s guest post comes from Josh Marsh, Vice President and General Manager at Cardinal Health Sonexus™ Access and Patient Support.

Josh examines the risks manufacturers take when transitioning a patient services hub from one vendor to another. He argues that scaling with a proven, flexible blueprint can help hubs with speed, patient continuity, and confident decision-making.

To learn more, download Cardinal Health Sonexus™ Access and Patient Support’s framework: 5 Questions Every Manufacturer Should Ask Before a Hub Transition.

Read on for Josh’s insights.

Read more »

© 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 73
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies

Next week, the Drug Channels Institute (DCI) will release our 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This 17th edition provides our most comprehensive and up-to-date examination of the U.S. drug pricing, reimbursement, and dispensing system. For 2025, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialty […]
3 min read
0
  1. Media & Marketing

The Industry Doesn’t Have an Access Collaboration Problem. It Has an Accountability Problem.

Today’s guest post comes from Jen Norton, President, Market Access & Value at EVERSANA. Jen examines why fragmented ownership across development, regulatory, pricing, distribution, and field functions undermines access at launch. She argues that naming a single accountable owner for the access outcome can close “access debt” earlier, reduce pre-launch friction, and turn coverage into […]
2 min read
0
  1. Uncategorized

Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Drivers, Impact on Coverage from the IRA, and a Drug Price Adventure

By Bryce Platt, PharmD Kids are heading back to school, but the drug channel never stops handing out homework. Fortunately, we did some of the research prep for you. In this issue: HRSA’s Revised 340B Rebate Model Pilot Households Feel the Cost of Prescription Drugs More The Drivers of Specialty Drug Spending Lost Brand Coverage […]
2 min read
0
  1. Media & Marketing

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels outlook 2026. I’ll be discussing why and how the gross-to-net bubble will be deflating. Click here to see the original post from July 2025. Is the gross-to-net bubble—the ever-widening gap between brand-name drug sales at list prices and […]
2 min read
0
  1. Data & Insights

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx. Laura suggests that manufacturers must move beyond payer-centric models toward integrated, direct-to-consumer and employer channel strategies that connect pricing, demand, and fulfillment. She argues that this approach will help manufacturers convert patient intent into therapy initiation while expanding access […]
2 min read
0
  1. Trends & External Forces

PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (VIDEO)

Here at Drug Channels, we’ve been closely tracking the evolution of the pharmacy benefit management (PBM) industry for many years. The short video below—excerpted from DCI’s recent PBM Industry Update 2026: Trends, Challenges, and What’s Ahead video webinar—reviews the shifting market positions of the largest PBMs and explains why vertical integration continues to reshape the […]
3 min read
0
  1. Trends & External Forces

The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)

This week, we’re rerunning some popular posts while we prepare for Friday’s live video webinar: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders. Click here to see the original post from March 2026. By Adam J. Fein, Ph.D. Next week, the Drug Channels Institute (DCI) will release our 2026 Economic […]
2 min read
0
  1. Associates & Employees

Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains

By Adam J. Fein, Ph.D. and Greis Kapexhiu It’s time for Drug Channels’ annual look at pharmacist salaries and employment. The latest data might be a tough pill to swallow. As we predicted, the situation was grim for retail pharmacists. Employment in retail outpatient pharmacies fell by 8,200 positions in 2025, following a drop of […]
2 min read
0

Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 12, 2026, Drug Channels Institute will release our 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The U.S. prescription drug market continues to expand, but the foundations of the drug channel are shifting. Legislative intervention, pricing realignment, vertical integration, and alternative payment models are accelerating a transition away from a rebate-driven system […]
3 min read
0
  1. Media & Marketing

The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?

By Adam J. Fein, Ph.D. The 340B Drug Pricing Program continues to redefine the meaning of “skyrocketing.” For 2025, discounted purchases under the 340B program reached an astounding $100 billion—23% higher than in 2024. The gross-to-net difference between list prices and discounted 340B purchases—a proxy for funds available to covered entities—also grew, to $79.5 billion […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026

Happy New Year, everyone! As always, thank you for welcoming Drug Channels into your inboxes, browsers, and apps. I’m continually inspired by the diverse and thoughtful people who follow, share, and challenge our work. Our DCI community now includes more than 110,000 subscribers and followers across the industry. If you haven’t already done so, you […]
2 min read
0
  1. Trends & External Forces

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground

By Adam J. Fein, Ph.D. Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. For 2025, DCI has identified more than 1,900 dispensing locations with specialty pharmacy accreditation from one or both of the two major independent accreditation organizations. The overall number of accredited locations […]
2 min read
0
  1. Data & Insights

Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 14, 2025, Drug Channels Institute will release our 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our sixteenth edition—is the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. With 9 chapters, 400+ pages, 187 exhibits, and 850+ endnotes, this report is unmatched in […]
3 min read
0

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)

This week, we’re rerunning some popular posts while we put the finishing touches on DCI’s 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2026. By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over lower-cost generics. […]
2 min read
0
  1. Uncategorized

BlinkRx Insights: Beyond the Hub – Rethinking the Prescription Journey

Today’s guest post comes from Geoffrey Chaiken and Matthew Chaiken, Co-founders of BlinkRx. Geoffrey and Matthew examine how efforts to improve patient access have contributed to an increasingly fragmented prescription journey. They suggest that a more integrated approach can reduce complexity, improve visibility and control for manufacturers, and create a simpler path to therapy for […]
2 min read
0
  1. Trends & External Forces

Drug Channels Leadership Forum 2026: Request an Invitation Before It’s Too Late!

The 2026 Drug Channels Leadership Forum (DCLF) is coming soon! Our second annual event will take place March 16–18, 2026, at the Turnberry Resort & Spa in Miami. Once again, Drug Channels Institute (DCI) is proud to host this invite-only gathering of senior leaders across the drug channel ecosystem. You must request an invitation to […]
3 min read
0
  1. Corporate Strategy

The $90 Billion Leakage Problem: How RIS Rx Helps Pharma Recover Lost Revenue

Today’s guest post comes from Gerard Rivera, CEO and Co-Founder of RIS Rx. Gerard explores how pharma companies lose billions each year through copay program inefficiencies, accumulators, maximizers, and other forms of systemic leakage. He introduces RIS Rx, a healthcare technology company whose platform helps manufacturers mitigate gross-to-net (GTN) revenue leakage while supporting patient access […]
2 min read
0
  1. Media & Marketing

The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy

Today’s guest post comes from Nareda Mills, President of Patient Solutions at Inizio Engage. Nareda examines how growing access complexity is reshaping specialty commercialization. She explores the emerging role of Non-Dispensing Pharmacies (NDPs) and argues that by improving coordination, visibility, and patient engagement, they can accelerate time-to-therapy and create a more seamless access experience. Click […]
2 min read
0
  1. Data & Insights

Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26

Today’s guest post comes from Chrissy Hand, Chief Product and Commercial Officer at CoverMyMeds. Chrissy highlights key themes in the future of patient access. She argues that policy changes, complex benefit designs, and affordability challenges require patient support services to be faster, more connected, and better aligned with real-world patient and provider needs. Join CoverMyMeds’ […]
2 min read
0
  1. Data & Insights

Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences

Today’s guest post comes from Allison Bridges, SVP Client Success at PHIL Inc. and Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals Allison and Cindy argue that many direct-to-patient (DTP) programs remain constrained by one-size-fits-all models that limit both patient experience and commercial performance. As patients increasingly expect convenience, choice, and price transparency, they suggest […]
2 min read
0
Next